In a recent study assessing long-term SCLC survivors, the ratio of CD68-positive MPs to CD3-positive T lymphocytes (CD68/CD3) were lower in long-term survivors (survival >4 years) than in those who survived for the expected amount of time. This evidence concerns the gene CD68 and small cell lung carcinoma.